Document is current
Any future updates will be listed below
-
Authors
Terpos, Evangelos https://orcid.org/0000-0001-5133-1422
Engelhardt, Monika
Cook, Gordon
Gay, Francesca
Mateos, Maria-Victoria https://orcid.org/0000-0003-2390-1218
Ntanasis-Stathopoulos, Ioannis https://orcid.org/0000-0002-6328-9783
van de Donk, Niels W. C. J.
Avet-Loiseau, Hervé
Hajek, Roman
Vangsted, Annette Juul https://orcid.org/0000-0002-2131-731X
Ludwig, Heinz https://orcid.org/0000-0002-3302-8726
Zweegman, Sonja
Moreau, Philippe
Einsele, Hermann
Boccadoro, Mario
San Miguel, Jesus
Dimopoulos, Meletios A.
Sonneveld, Pieter
- License Information
-
More Information
Article History
Received: 29 April 2020
Revised: 6 May 2020
Accepted: 13 May 2020
First Online: 22 May 2020
Compliance with ethical standards
:
: ET declares honoraria from BMS, Janssen, Celgene, Takeda, Genesis Pharma, Amgen and Novartis; research funding from Janssen, Amgen, Takeda and Genesis Pharma; ME declares no competing financial interests for this paper; GC declares Honoraria: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Sanofi, Karyopharm and GSK; Research funding: Celgene, Janssen, Takeda; FG declares honoraria from BMS, Janssen, Celgene, Takeda, Amgen; advisory board from Janssen, Amgen, Takeda, Adaptive, Celgene, Oncopeptides, Roche, Abbvie, GSK; M-VM has received honoraria from lectures and boards from: Janssen, Celgene, Amgen, Takeda, Abbvie, GSK, Adaptive, Roche, Seattle Genetics; IN-S declares no competing financial interests for this paper; NWCJD has received research support from Janssen Pharmaceuticals, AMGEN, Celgene, Novartis, and BMS, serves in advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Takeda, Roche, Novartis, Bayer, and Servier; HA-L declares no competing financial interests for this paper; RH has received research funding from Janssen, Amgen, Celgene, BMS, Novartis and Takeda, serves in advisory boards for Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar and Takeda, and has received honoraria from Janssen, Amgen, Celgene, BMS, Pharma Mar and Takeda; AJV declares no competing financial interests for this paper; HL has received research funding from Takeda, Amgen, serves in Speaker’s Bureau/Advisory Boards for Takeda, Amgen, Janssen, Celgene, Sanofi, Seattle Genetics and Bristol-Meyers. SZ has received research funding from Takeda and Janssen and serves in advisory boards for Celgene, Takeda, Janssen, Sanofi and Oncopeptides; PM declares honorarium form Celgene, Janssen, Takeda, Amgen and Abbvie; HE has received honoraria and declares consultancy for Janssen, Celgene, BMS, Amgen, Novartis and Takeda, and received research support from Janssen, Celgene, BMS, Amgen. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma; JSM declares consultancy for Amgen, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, GSK Takeda, Sanofi, and Roche; MAD declares consultancy and honoraria from Janssen, Celgene, Takeda, Amgen and BMS; PS declares research funding from Amgen, Celgene, Janssen, Karyopharm, SkylineDx and Takeda and honoraria from Amgen, BMS, Celgene, Janssen, Karyopharm and Takeda.
Free to read: This content has been made available to all.
